TPX2/Aurora kinase A signaling as a potential therapeutic target in genomically unstable cancer cells

Prognostic importance of Aurora Kinases and mitotic spindle genes transcript levels in Myelodysplastic syndrome

(2018) Daniela de Paula Borges et al.   LEUKEMIA RESEARCH

Pan-cancer analysis distinguishes transcriptional changes of aneuploidy from proliferation

(2017) Christopher Buccitelli et al.   GENOME RESEARCH

Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer

(2017) Ana Alcaraz-Sanabria et al.   MOLECULAR CANCER THERAPEUTICS

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures

(2017) Helen Davies et al.   NATURE MEDICINE

TPX2 expression is associated with poor survival in gastric cancer

(2017) Chiharu Tomii et al.   World Journal of Surgical Oncology

Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells

(2017) Pepijn M. Schoonen et al.   Nature Communications

876ORANDOMIZED PHASE 2 STUDY OF INVESTIGATIONAL, SELECTIVE AURORA A KINASE INHIBITOR ALISERTIB (MLN8237) WITH WEEKLY PACLITAXEL VS PACLITAXEL ALONE IN PATIENTS (PTS) WITH RECURRENT OVARIAN CANCER (OC)

(2017) R. Coleman et al.   ANNALS OF ONCOLOGY

Validation of TPX2 as a novel prognostic marker for malignant progression and metastasis of colon cancer.

(2017) Ping Wei et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma

(2016) M. A. Dickson et al.   ANNALS OF ONCOLOGY

Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors

(2016) Julie N. Graff et al.   CANCER

A MYC–aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer

(2016) Daniel Dauch et al.   NATURE MEDICINE

CHK2–BRCA1tumor-suppressor axis restrains oncogenic Aurora-A kinase to ensure proper mitotic microtubule assembly

(2016) Norman Ertych et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC

(2015) Y. Takahashi et al.   ANNALS OF ONCOLOGY

Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108

(2015) Paul M. Barr et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study

(2015) Bohuslav Melichar et al.   LANCET ONCOLOGY

Gene expression analysis identifies global gene dosage sensitivity in cancer

(2015) Rudolf S N Fehrmann et al.   NATURE GENETICS

A haploid genetic screen identifies the G1/S regulatory machinery as a determinant of Wee1 inhibitor sensitivity

(2015) Anne Margriet Heijink et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Translational Exposure-Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib)

(2014) J. J. Huck et al.   MOLECULAR CANCER THERAPEUTICS

RAN Nucleo-Cytoplasmic Transport and Mitotic Spindle Assembly Partners XPO7 and TPX2 Are New Prognostic Biomarkers in Serous Epithelial Ovarian Cancer

(2014) Katia Y. Cáceres-Gorriti et al.   PLoS One

Triple-Negative Breast Cancer and the Need for New Therapeutic Targets

(2013) Olav Engebraaten et al.   AMERICAN JOURNAL OF PATHOLOGY

How unfinished business from S-phase affects mitosis and beyond

(2013) Hocine W Mankouri et al.   EMBO JOURNAL

Emerging landscape of oncogenic signatures across human cancers

(2013) Giovanni Ciriello et al.   NATURE GENETICS

Repair of Strand Breaks by Homologous Recombination

(2013) M. Jasin et al.   Cold Spring Harbor Perspectives in Biology

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

(2012) Ursula A. Matulonis et al.   GYNECOLOGIC ONCOLOGY

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

(2012) Sohrab P. Shah et al.   NATURE

DNA breaks and chromosome pulverization from errors in mitosis

(2012) Karen Crasta et al.   NATURE

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response

(2012) Britt Adamson et al.   NATURE CELL BIOLOGY

Genetic Interactions in Cancer Progression and Treatment

(2011) Alan Ashworth et al.   CELL

Chromosome Segregation Errors as a Cause of DNA Damage and Structural Chromosome Aberrations

(2011) A. Janssen et al.   SCIENCE

Drug-Resistant Aurora A Mutants for Cellular Target Validation of the Small Molecule Kinase Inhibitors MLN8054 and MLN8237

(2010) Dominic A. Sloane et al.   ACS Chemical Biology

Poleward Transport of TPX2 in the Mammalian Mitotic Spindle Requires Dynein, Eg5, and Microtubule Flux

(2010) Nan Ma et al.   MOLECULAR BIOLOGY OF THE CELL

Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis

(2010) Mary Ellen Moynahan et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

A Genome-Scale DNA Repair RNAi Screen Identifies SPG48 as a Novel Gene Associated with Hereditary Spastic Paraplegia

(2010) Mikołaj Słabicki et al.   PLOS BIOLOGY

A Mitotic Phosphorylation Feedback Network Connects Cdk1, Plk1, 53BP1, and Chk2 to Inactivate the G2/M DNA Damage Checkpoint

(2010) Marcel A. T. M. van Vugt et al.   PLOS BIOLOGY

Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction

(2009) Ji Luo et al.   CELL

Overexpression of the receptor for hyaluronan-mediated motility, correlates with expression of microtubule-associated protein in human oral squamous cell carcinomas

(2009) Shigeishi   INTERNATIONAL JOURNAL OF ONCOLOGY

Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin

(2008) B. Evers et al.   CLINICAL CANCER RESEARCH

The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome

(2008) Jens K. Habermann et al.   INTERNATIONAL JOURNAL OF CANCER

Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery

(2008) Libor Macůrek et al.   NATURE

Genome instability: a mechanistic view of its causes and consequences

(2008) Andrés Aguilera et al.   NATURE REVIEWS GENETICS

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

(2008) S. Rottenberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA